116 related articles for article (PubMed ID: 37549739)
21. STMN1 upregulation mediates hepatocellular carcinoma and hepatic stellate cell crosstalk to aggravate cancer by triggering the MET pathway.
Zhang R; Gao X; Zuo J; Hu B; Yang J; Zhao J; Chen J
Cancer Sci; 2020 Feb; 111(2):406-417. PubMed ID: 31785057
[TBL] [Abstract][Full Text] [Related]
22. Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells.
Firtina Karagonlar Z; Koc D; Iscan E; Erdal E; Atabey N
Cancer Sci; 2016 Apr; 107(4):407-16. PubMed ID: 26790028
[TBL] [Abstract][Full Text] [Related]
23. Yes-associated protein (YAP) induces a secretome phenotype and transcriptionally regulates plasminogen activator Inhibitor-1 (PAI-1) expression in hepatocarcinogenesis.
Marquard S; Thomann S; Weiler SME; Bissinger M; Lutz T; Sticht C; Tóth M; de la Torre C; Gretz N; Straub BK; Marquardt J; Schirmacher P; Breuhahn K
Cell Commun Signal; 2020 Oct; 18(1):166. PubMed ID: 33097058
[TBL] [Abstract][Full Text] [Related]
24. Hepatitis B virus X protein promotes hepatocellular carcinoma transformation through interleukin-6 activation of microRNA-21 expression.
Li CH; Xu F; Chow S; Feng L; Yin D; Ng TB; Chen Y
Eur J Cancer; 2014 Oct; 50(15):2560-9. PubMed ID: 25087183
[TBL] [Abstract][Full Text] [Related]
25. Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features.
Zhu C; Ho YJ; Salomao MA; Dapito DH; Bartolome A; Schwabe RF; Lee JS; Lowe SW; Pajvani UB
J Hepatol; 2021 Mar; 74(3):613-626. PubMed ID: 33038431
[TBL] [Abstract][Full Text] [Related]
26. MiR-181a-5p is downregulated in hepatocellular carcinoma and suppresses motility, invasion and branching-morphogenesis by directly targeting c-Met.
Korhan P; Erdal E; Atabey N
Biochem Biophys Res Commun; 2014 Aug; 450(4):1304-12. PubMed ID: 25058462
[TBL] [Abstract][Full Text] [Related]
27. Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma.
Ke AW; Shi GM; Zhou J; Wu FZ; Ding ZB; Hu MY; Xu Y; Song ZJ; Wang ZJ; Wu JC; Bai DS; Li JC; Liu KD; Fan J
Hepatology; 2009 Feb; 49(2):491-503. PubMed ID: 19065669
[TBL] [Abstract][Full Text] [Related]
28. Keratin 19 Expression in Hepatocellular Carcinoma Is Regulated by Fibroblast-Derived HGF via a MET-ERK1/2-AP1 and SP1 Axis.
Rhee H; Kim HY; Choi JH; Woo HG; Yoo JE; Nahm JH; Choi JS; Park YN
Cancer Res; 2018 Apr; 78(7):1619-1631. PubMed ID: 29363547
[TBL] [Abstract][Full Text] [Related]
29. IL-6/STAT3 axis initiated CAFs via up-regulating TIMP-1 which was attenuated by acetylation of STAT3 induced by PCAF in HCC microenvironment.
Zheng X; Xu M; Yao B; Wang C; Jia Y; Liu Q
Cell Signal; 2016 Sep; 28(9):1314-1324. PubMed ID: 27297362
[TBL] [Abstract][Full Text] [Related]
30. P21-activated protein kinase is overexpressed in hepatocellular carcinoma and enhances cancer metastasis involving c-Jun NH2-terminal kinase activation and paxillin phosphorylation.
Ching YP; Leong VY; Lee MF; Xu HT; Jin DY; Ng IO
Cancer Res; 2007 Apr; 67(8):3601-8. PubMed ID: 17440071
[TBL] [Abstract][Full Text] [Related]
31. Regulation of MET receptor tyrosine kinase signaling by suppressor of cytokine signaling 1 in hepatocellular carcinoma.
Gui Y; Yeganeh M; Donates YC; Tobelaim WS; Chababi W; Mayhue M; Yoshimura A; Ramanathan S; Saucier C; Ilangumaran S
Oncogene; 2015 Nov; 34(46):5718-28. PubMed ID: 25728680
[TBL] [Abstract][Full Text] [Related]
32. c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma.
You H; Ding W; Dang H; Jiang Y; Rountree CB
Hepatology; 2011 Sep; 54(3):879-89. PubMed ID: 21618573
[TBL] [Abstract][Full Text] [Related]
33. Cooperative interaction of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis.
Bozkaya G; Korhan P; Cokaklı M; Erdal E; Sağol O; Karademir S; Korch C; Atabey N
Mol Cancer; 2012 Sep; 11():64. PubMed ID: 22962849
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic upregulation of HGF and c-Met drives metastasis in hepatocellular carcinoma.
Ogunwobi OO; Puszyk W; Dong HJ; Liu C
PLoS One; 2013; 8(5):e63765. PubMed ID: 23723997
[TBL] [Abstract][Full Text] [Related]
35. Exosome-mediated secretion of LOXL4 promotes hepatocellular carcinoma cell invasion and metastasis.
Li R; Wang Y; Zhang X; Feng M; Ma J; Li J; Yang X; Fang F; Xia Q; Zhang Z; Shang M; Jiang S
Mol Cancer; 2019 Jan; 18(1):18. PubMed ID: 30704479
[TBL] [Abstract][Full Text] [Related]
36. Characterization of genome-wide TFCP2 targets in hepatocellular carcinoma: implication of targets FN1 and TJP1 in metastasis.
Xu X; Liu Z; Zhou L; Xie H; Cheng J; Ling Q; Wang J; Guo H; Wei X; Zheng S
J Exp Clin Cancer Res; 2015 Jan; 34(1):6. PubMed ID: 25609232
[TBL] [Abstract][Full Text] [Related]
37. Loss of Pten synergizes with c-Met to promote hepatocellular carcinoma development via mTORC2 pathway.
Xu Z; Hu J; Cao H; Pilo MG; Cigliano A; Shao Z; Xu M; Ribback S; Dombrowski F; Calvisi DF; Chen X
Exp Mol Med; 2018 Jan; 50(1):e417. PubMed ID: 29303510
[TBL] [Abstract][Full Text] [Related]
38. PRMT9 promotes hepatocellular carcinoma invasion and metastasis via activating PI3K/Akt/GSK-3β/Snail signaling.
Jiang H; Zhou Z; Jin S; Xu K; Zhang H; Xu J; Sun Q; Wang J; Xu J
Cancer Sci; 2018 May; 109(5):1414-1427. PubMed ID: 29603830
[TBL] [Abstract][Full Text] [Related]
39. An essential role of RNF187 in Notch1 mediated metastasis of hepatocellular carcinoma.
Zhang L; Chen J; Yong J; Qiao L; Xu L; Liu C
J Exp Clin Cancer Res; 2019 Sep; 38(1):384. PubMed ID: 31477177
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-449a suppresses hepatocellular carcinoma cell growth via G1 phase arrest and the HGF/MET c-Met pathway.
Cheng J; Wu LM; Deng XS; Wu J; Lv Z; Zhao HF; Yang Z; Ni Y
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):336-344. PubMed ID: 30108016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
